Staphylococcus aureus induce drug resistance in cancer T cells in Sézary Syndrome
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Staphylococcus aureus induce drug resistance in cancer T cells in Sézary Syndrome. / Vadivel, Chella Krishna; Willerslev-Olsen, Andreas; Namini, Martin Rich Javadi; Zeng, Ziao; Yan, Lang; Danielsen, Maria; Gluud, Maria; Pallesen, Emil Marek Heymans; Wojewoda, Karolina; Osmancevic, Amra; Hedebo, Signe; Chang, Yun-Tsan; Lindahl, Lise M; Koralov, Sergei B; Geskin, Larisa J; Bates, Susan E; Iversen, Lars; Litman, Thomas; Bech, Rikke; Wobser, Marion; Guenova, Emmanuella; Kamstrup, Maria R; Odum, Niels; Buus, Terkild B.
In: Blood, 03.01.2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Staphylococcus aureus induce drug resistance in cancer T cells in Sézary Syndrome
AU - Vadivel, Chella Krishna
AU - Willerslev-Olsen, Andreas
AU - Namini, Martin Rich Javadi
AU - Zeng, Ziao
AU - Yan, Lang
AU - Danielsen, Maria
AU - Gluud, Maria
AU - Pallesen, Emil Marek Heymans
AU - Wojewoda, Karolina
AU - Osmancevic, Amra
AU - Hedebo, Signe
AU - Chang, Yun-Tsan
AU - Lindahl, Lise M
AU - Koralov, Sergei B
AU - Geskin, Larisa J
AU - Bates, Susan E
AU - Iversen, Lars
AU - Litman, Thomas
AU - Bech, Rikke
AU - Wobser, Marion
AU - Guenova, Emmanuella
AU - Kamstrup, Maria R
AU - Odum, Niels
AU - Buus, Terkild B
N1 - Copyright © 2024 American Society of Hematology.
PY - 2024/1/3
Y1 - 2024/1/3
N2 - Patients with Sézary syndrome (SS), a leukemic variant of cutaneous T cell lymphoma (CTCL), are prone to Staphylococcus aureus (S. aureus) infections and have a poor prognosis due to treatment-resistance. Here, we report that S. aureus and staphylococcal enterotoxins (SE) induce drug resistance in malignant T-cells against therapeutics commonly used in CTCL. Supernatant from patient-derived, SE-producing S. aureus and recombinant SE significantly inhibit cell death induced by HDAC inhibitor romidepsin in primary malignant T-cells from SS patients. Bacterial killing by engineered, bacteriophage-derived, S. aureus-specific endolysin (XZ.700) abrogates the effect of S. aureus supernatant. Likewise, mutations in MHC Class II binding sites of SE type-A (SEA) and anti-SEA antibody block induction of resistance. Importantly, SE also triggers resistance to other HDAC inhibitors (vorinostat and resminostat) and chemotherapeutic drugs (doxorubicin and etoposide). Multimodal single-cell sequencing indicates TCR, NFB, and JAK/STAT signaling pathways (previously associated with drug-resistance) as putative mediators of SE-induced drug resistance. In support, inhibition of TCR-signaling and Protein Kinase C (upstream of NFB) counteracts SE-induced rescue from drug-induced cell death. Inversely, SE cannot rescue from cell death induced by proteasome/NFB inhibitor bortezomib. Inhibition of JAK/STAT only blocks SE-induced rescue of malignant T-cells in some but not all patients, suggesting two distinct ways SE can induce drug resistance. In conclusion, we show that S. aureus enterotoxins induce drug-resistance in primary malignant T-cells. These findings suggest that S. aureus enterotoxins cause clinical treatment-resistance in SS patients and that anti-bacterial measures may improve the outcome of cancer-directed therapy in patients harboring S. aureus.
AB - Patients with Sézary syndrome (SS), a leukemic variant of cutaneous T cell lymphoma (CTCL), are prone to Staphylococcus aureus (S. aureus) infections and have a poor prognosis due to treatment-resistance. Here, we report that S. aureus and staphylococcal enterotoxins (SE) induce drug resistance in malignant T-cells against therapeutics commonly used in CTCL. Supernatant from patient-derived, SE-producing S. aureus and recombinant SE significantly inhibit cell death induced by HDAC inhibitor romidepsin in primary malignant T-cells from SS patients. Bacterial killing by engineered, bacteriophage-derived, S. aureus-specific endolysin (XZ.700) abrogates the effect of S. aureus supernatant. Likewise, mutations in MHC Class II binding sites of SE type-A (SEA) and anti-SEA antibody block induction of resistance. Importantly, SE also triggers resistance to other HDAC inhibitors (vorinostat and resminostat) and chemotherapeutic drugs (doxorubicin and etoposide). Multimodal single-cell sequencing indicates TCR, NFB, and JAK/STAT signaling pathways (previously associated with drug-resistance) as putative mediators of SE-induced drug resistance. In support, inhibition of TCR-signaling and Protein Kinase C (upstream of NFB) counteracts SE-induced rescue from drug-induced cell death. Inversely, SE cannot rescue from cell death induced by proteasome/NFB inhibitor bortezomib. Inhibition of JAK/STAT only blocks SE-induced rescue of malignant T-cells in some but not all patients, suggesting two distinct ways SE can induce drug resistance. In conclusion, we show that S. aureus enterotoxins induce drug-resistance in primary malignant T-cells. These findings suggest that S. aureus enterotoxins cause clinical treatment-resistance in SS patients and that anti-bacterial measures may improve the outcome of cancer-directed therapy in patients harboring S. aureus.
U2 - 10.1182/blood.2023021671
DO - 10.1182/blood.2023021671
M3 - Journal article
C2 - 38170178
JO - Blood
JF - Blood
SN - 0006-4971
ER -
ID: 385982550